Abstract: A semiconductor device includes a first semiconductor structure that includes a first substrate, circuit devices on the first substrate, a lower interconnection structure, and a lower bonding structure; and a second semiconductor structure disposed on and connected to the first semiconductor structure The second semiconductor structure includes a stack structure; channel structures that including a first portion that penetrate through the stack structure in the vertical direction and a second portion that extends upward from the first portion; a first material layer disposed on the stack structure and the channel structure and having first conductivity; and a second material layer disposed between the first material layer and the stack structure and having second conductivity., The first material layer overlaps second portions of the channel structures in the vertical direction, and the second material layer does not overlap the second portions of the channel structures in the vertical direction.

Abstract: A memory device includes first and second semiconductor layers. The first semiconductor layer includes wordlines and bitlines, an upper substrate, and a memory cell array. The memory cell array includes a memory blocks. The second semiconductor layer includes a lower substrate, and an address decoder. Each memory block includes a core region including a memory cells, a first extension region adjacent to a first side of the core region and including a plurality of wordline contacts, and a second extension region adjacent to a second side of the core region and including an insulating mold structure. The second extension region includes step zones and at least one flat zone. Through-hole vias penetrating the insulating mold structure are in the flat zone. The wordlines and the address decoder are electrically connected with each other by at least the through-hole vias.

Abstract: A method for lowering blood pressure is disclosed. The method includes administering a pharmaceutical composition to a subject in need thereof, wherein the composition contains a pharmaceutically acceptable excipient; and a peptide having an amino acid sequence of any one of SEQ ID NOS: 1 to 102. The peptide is in a form of a long-acting conjugate.

Abstract: Provided are a pharmaceutical composition including a long-acting conjugate of a triple agonist as an active ingredient and a method of treating obesity and/or a non-alcoholic fatty liver disease using the same. The pharmaceutical composition including the long-acting conjugate of the triple agonist of the present invention may be stably applied to treatment of obesity and/or a non-alcoholic fatty liver disease without side effects according to therapeutic effects on obesity and/or the non-alcoholic fatty liver disease.